ArticlePloS one2012
Differential gene expression in tamoxifen-resistant breast cancer cells revealed by a new analytical model of RNA-Seq data.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 62 citations in OpenAlex.
- Quantitative Assessment of PALB2 and BRIP1 Genes Expression in the Breast Cancer Cell Line under the Influence of Tamoxifen.Galen medical journal · 2023Article
- Clinical significance and prognostic value of small nucleolar RNA SNORA38 in breast cancer.Frontiers in oncology · 2022Article
- Relationship between metabolic reprogramming and drug resistance in breast cancer.Frontiers in oncology · 2022Review
- The Potential Role of Small Nucleolar RNAs in Cancers - An Evidence Map.International journal of general medicine · 2022Review
- ELOVL2: a novel tumor suppressor attenuating tamoxifen resistance in breast cancer.American journal of cancer research · 2021Article
- Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.Breast cancer research : BCR · 2020Article
- Identification of a mechanogenetic link between substrate stiffness and chemotherapeutic response in breast cancer.Biomaterials · 2019Article
- Time resolved gene expression analysis during tamoxifen adaption of MCF-7 cells identifies long non-coding RNAs with prognostic impact.RNA biology · 2019Article
- Splicing factorEMBO reports · 2019Article
- Review
- Cell cycle-dependent force transmission in cancer cells.Molecular biology of the cell · 2018Article
- Transcriptome profiling identified differentially expressed genes and pathways associated with tamoxifen resistance in human breast cancer.Oncotarget · 2018Article
- Article
- Glucose impairs tamoxifen responsiveness modulating connective tissue growth factor in breast cancer cells.Oncotarget · 2017Article
- Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy.Oncotarget · 2017Article
- Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- HDAC2 and HDAC5 Up-Regulations Modulate Survivin and miR-125a-5p Expressions and Promote Hormone Therapy Resistance in Estrogen Receptor Positive Breast Cancer Cells.Frontiers in pharmacology · 2017Article
- OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.Oncogene · 2016Article
- Genome-Wide Analysis Identifies Germ-Line Risk Factors Associated with Canine Mammary Tumours.PLoS genetics · 2016Article
- Genome-wide transcriptional regulation of estrogen receptor targets in fallopian tube cells and the role of selective estrogen receptor modulators.Journal of ovarian research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance to tamoxifen (Tam), a widely used antagonist of the estrogen receptor (ER), is a common obstacle to successful breast cancer treatment. While adjuvant therapy with Tam has been shown to significantly decrease the rate of disease recurrence and mortality, recurrent disease occurs in one third of patients treated with Tam within 5 years of therapy. A better understanding of gene expression alterations associated with Tam resistance will facilitate circumventing this problem. Using a next generation sequencing approach and a new bioinformatics model, we compared the transcriptomes of Tam-sensitive and Tam-resistant breast cancer cells for identification of genes involved in the development of Tam resistance. We identified differential expression of 1215 mRNA and 513 small RNA transcripts clustered into ERα functions, cell cycle regulation, transcription/translation, and mitochondrial dysfunction. The extent of alterations found at multiple levels of gene regulation highlights the ability of the Tam-resistant cells to modulate global gene expression. Alterations of small nucleolar RNA, oxidative phosphorylation, and proliferation processes in Tam-resistant cells present areas for diagnostic and therapeutic tool development for combating resistance to this anti-estrogen agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.